CytRx to Present at the Jefferies 2014 Global Healthcare Conference

  CytRx to Present at the Jefferies 2014 Global Healthcare Conference

Jefferies 2014 Global Healthcare Conference

Business Wire

LOS ANGELES -- May 29, 2014

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that President and CEO
Steven A. Kriegsman and Vice President of Business Development David Haen will
present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June
4, 2014 at 9:30 a.m. Eastern Time. The conference is being held June 2-5 in
New York City.

A live and archived webcast of the presentation will be available on the
Company’s website at www.cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. CytRx currently is focused on the clinical
development of aldoxorubicin (formerly known as INNO-206), its improved
version of the widely used chemotherapeutic agent doxorubicin. CytRx has
completed a global Phase 2b clinical trial with aldoxorubicin as a first-line
therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the
same indication, a Phase 1b study of aldoxorubicin in combination with
doxorubicin in patients with advanced solid tumors and a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors.
CytRx recently initiated, under a special protocol assessment, a pivotal Phase
3 global trial with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with chemotherapy.
The Company also recently announced that it has received approval from the FDA
to continue dosing patients with aldoxorubicin until disease progression in
that clinical trial. CytRx has initiated a Phase 2 clinical trial with
aldoxorubicin in patients with late-stage glioblastoma (brain cancer), and a
Phase 2 clinical trial in HIV-related Kaposi’s sarcoma. CytRx plans to expand
its pipeline of oncology candidates based on a linker platform technology that
can be utilized with multiple chemotherapeutic agents and may allow for
greater concentration of drug at tumor sites. CytRx also has rights to two
additional drug candidates, tamibarotene and bafetinib. CytRx completed its
evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk
B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for
further development of bafetinib. For more information about CytRx
Corporation, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements, including risks relating to the outcome, timing
and results of CytRx's clinical trials, the risk that any future human testing
of aldoxorubicin might not produce results similar to those seen in past human
or animal testing, risks related to CytRx's ability to manufacture its drug
candidates in a timely fashion, cost-effectively or in commercial quantities
in compliance with stringent regulatory requirements, risks related to CytRx's
need for additional capital or strategic partnerships to fund its ongoing
working capital needs and development efforts, including the Phase 3 clinical
development of aldoxorubicin, risks related to lawsuits that have been brought
against the Company and its officers and/or directors for alleged violations
of the securities laws, and the risks and uncertainties described in the most
recent annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of CytRx's most
recent annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Investor Relations:
Argot Partners
Michelle Carroll
212-600-1902
michelle@argotpartners.com
or
Media:
Argot Partners
Eliza Schleifstein
973-361-1546
eliza@argotpartners.com
or
Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development
310-826-5648, x304
dhaen@cytrx.com
 
Press spacebar to pause and continue. Press esc to stop.